DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Crenolanib is an investigational drug.
There have been 17 clinical trials for Crenolanib. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2016.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Arog Pharmaceuticals, Inc., St. Jude Children's Research Hospital, and Centre Leon Berard.
There are ten US patents protecting this investigational drug and one hundred and forty-one international patents.
Recent Clinical Trials for Crenolanib
|A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia||Arog Pharmaceuticals, Inc.||Phase 2|
|Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML||Arog Pharmaceuticals, Inc.||Phase 3|
|Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML||Arog Pharmaceuticals, Inc.||Phase 3|
Top disease conditions for Crenolanib
Top clinical trial sponsors for Crenolanib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Crenolanib||Start Trial||Method of inhibiting mutant C-KIT||Arog Pharmaceuticals, Inc. (Dallas, TX)||Start Trial|
|Crenolanib||Start Trial||Benzoimidazole derivatives useful as antiproliferative agents||Pfizer Inc (New York, NY)||Start Trial|
|Crenolanib||Start Trial||Processes for the preparation of benzoimidazole derivatives||Pfizer Inc (New York, NY)||Start Trial|
|Crenolanib||Start Trial||Method of inhibiting constitutively active phosphorylated FLT3 kinase||AROG Pharmaceuticals, LLC (Dallas, TX)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|